Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities

Clinical Immunology

Volumn 158, Issue 1, 2015, Pages 1-7

  Cedeno Laurent, Filiberto ^a   Singer, Elisha M ^a   Wysocka, Maria ^a   Benoit, Bernice M ^a   Vittorio, Carmela C ^a   Kim, Ellen J ^a   Yosipovitch, Gil ^b   Rook, Alain H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CTCL; IL 31; Immunotherapy; Pruritus

Indexed keywords

CHEMOKINE RECEPTOR CCR4; DEXAMETHASONE; INTERLEUKIN 31; MOGAMULIZUMAB; ROMIDEPSIN; VORINOSTAT; DEPSIPEPTIDE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; IL31 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MESSENGER RNA;

APOPTOSIS; ARTICLE; CUTANEOUS T CELL LYMPHOMA; DRUG TARGETING; EPIGENETICS; HUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PRURITUS; T LYMPHOCYTE; ADULT; AGED; COMPLICATION; DRUG EFFECTS; FEMALE; IMMUNOLOGY; IN VITRO STUDY; LYMPHOMA, T-CELL, CUTANEOUS; MALE; METABOLISM; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DEPSIPEPTIDES; DEXAMETHASONE; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; IN VITRO TECHNIQUES; INTERLEUKINS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; PRURITUS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN NEOPLASMS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84924985426     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.02.014     Document Type: Article

References (18)

1. Kim E.J., et al. Mycosis fungoides and Sezary syndrome: an update. Curr. Oncol. Rep. 2006, 8(5):376-386.
2. Ahern K., Gilmore E.S., Poligone B. Pruritus in cutaneous T-cell lymphoma: a review. J. Am. Acad. Dermatol. 2012, 67(4):760-768.
3. Guenova E., et al. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin. Cancer Res. 2013, 19(14):3755-3763.
4. Singer E.M., et al. IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus. J. Invest. Dermatol. 2013, 133(12):2783-2785.
5. Sonkoly E., et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J. Allergy Clin. Immunol. 2006, 117(2):411-417.
6. Maier E., et al. Human Th2 but not Th9 cells release IL-31 in a STAT6/NF-kappaB-dependent way. J. Immunol. 2014, 193(2):645-654.
7. Murphy G.F. Cutaneous T-cell lymphoma. Adv. Pathol. 1988, 1:131-156.
8. Lubowe I.I. Use of hydrocortisone and 9-alpha-fluorohydrocortisone derivatives; evaluation in the treatment of the pruritic dermatoses. AMA Arch. Dermatol. 1955, 72(2):164-170.
9. Olsen E.A., et al. Sezary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J. Am. Acad. Dermatol. 2011, 64(2):352-404.
10. Rangwala S., Zhang C., Duvic M. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. Futur. Med. Chem. 2012, 4(4):471-486.
11. Mann B.S., et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin. Cancer Res. 2007, 13(8):2318-2322.
12. Kim Y.H., et al. Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. Leuk. Lymphoma 2013, 54(2):284-289.
13. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26(37):5541-5552.
14. Ferenczi K., et al. Increased CCR4 expression in cutaneous T cell lymphoma. J. Invest. Dermatol. 2002, 119(6):1405-1410.
15. Ogura M., et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J. Clin. Oncol. 2014, 32(11):1157-1163.
16. Raap U., et al. IL-31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis. Pediatr. Allergy Immunol. 2012, 23(3):285-288.
17. Vowels B.R., et al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J. Invest. Dermatol. 1994, 103(5):669-673.
18. Cedeno-Laurent F., et al. Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma. Blood 2012, 119(15):3534-3538.